NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.500
+0.002 (0.13%)
Feb 11, 2026, 12:56 PM CET
NextCell Pharma AB Revenue
In the fiscal year ending August 31, 2025, NextCell Pharma AB had annual revenue of 11.06M SEK, down -1.90%. NextCell Pharma AB had revenue of 2.52M in the quarter ending August 31, 2025, with 48.67% growth.
Revenue
11.06M
Revenue Growth
-1.90%
P/S Ratio
15.10
Revenue / Employee
461.02K
Employees
24
Market Cap
167.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 11.06M | -213.75K | -1.90% |
| Aug 31, 2024 | 11.28M | -2.68M | -19.18% |
| Aug 31, 2023 | 13.96M | 7.73M | 124.03% |
| Aug 31, 2022 | 6.23M | 1.77M | 39.82% |
| Aug 31, 2021 | 4.46M | 288.92K | 6.94% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| IRLAB Therapeutics AB | 85.56M |
| Sprint Bioscience AB | 50.03M |
| Elicera Therapeutics AB | 13.70M |
| Biovica International AB | 9.89M |
| Simris Group AB (PUBL) | 2.30M |
| Karolinska Development AB | 1.74M |